Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
TORONTO, April 02, 2024 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB:RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s clinical study (the “Study”) (NCT05322954) evaluating the safety and feasibility of oral psilocybin as a potential treatment for methamphetamine use disorder conducted under an investigator-initiated IND at the University of Wisconsin-Madison, School of Medicine and Public Health and School of Pharmacy.
Related news for (RVVTF)
- Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
- Revive Therapeutics Advances with Next-Generation Bucillamine Development
- Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
- Revive Therapeutics Announces Proposed Shares for Debt Transaction
- Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment